Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.

ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic is having a catastrophic impact on human health¹. Widespread community transmission has triggered stringent distancing measures with severe socio-economic consequences. Gaining control of the pandemic will depend on the interruption of transmission chains until vaccine-induced or naturally acquired protective herd immunity arises. However, approved antiviral treatments such as remdesivir and reconvalescent serum cannot be delivered orally^2,3, making them poorly suitable for transmission control. We previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801 (refs. ^4,5), that was repurposed for use against severe acute respiratory syndr

SUBMITTER: Cox RM 

PROVIDER: S-EPMC7755744 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature